EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists

by NASDAQ Market News July 30, 2019

NASDAQ Market News
Click here to email author

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (nmCRPC)

ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019

Ads